NEW YORK (GenomeWeb) – Australian diagnostics firm SpeeDx announced today that it has incorporated a US-based subsidiary as it plans for the US launch of its ResistancePlus MG assay for the detection of antibiotic-resistant strains of Mycoplasma genitalium.

The subsidiary is expected to be located in Austin, Texas, a company spokesperson said.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.